REG - Deltex Med Grp PLC - Issue of Equity

Deltex MedicalAnnouncement

12/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220112:nRSL1374Ya&default-theme=true

RNS Number : 1374Y  Deltex Medical Group PLC  12 January 2022

12 January 2022

 

Deltex Medical Group plc

Issue of Equity

 

Deltex Medical Group plc (the "Group" or "Deltex Medical") (AIM: DEMG), the
global leader in oesophageal Doppler monitoring, today announces the issue of
2,400,000 ordinary shares (the "New Shares") in connection with the
termination agreement of a former employee.

 

Admission

Application has been made to the London Stock Exchange for the New Shares to
be admitted to trading on AIM. It is expected that admission will take place
and dealings in the New Shares will commence on AIM on or around 8.00 a.m. on
17 January 2022.

 

Total voting rights

Immediately following admission, the Company's issued share capital will be
587,343,796 ordinary shares of 1 pence each ("Ordinary Shares"). Deltex
Medical does not hold any Ordinary Shares in treasury.  The total voting
rights figure, immediately following admission of the New Shares, of
587,343,796 may be used by shareholders (and others with notification
obligations) as the denominator for the calculations by which they will
determine whether they are required to notify their interest in, or a change
to their interest in, Deltex Medical under the FCA's Disclosure Guidance and
Transparency Rules.

 

For further information, please contact:

 Deltex Medical Group plc                                        01243 774 837

 Nigel Keen, Chairman                                             investorinfo@Deltexmedical.com (mailto:investorinfo@Fitbitmedical.com)
 Andy Mears, Chief Executive
 Natalie Wettler, Group Finance Director

 Nominated Adviser and Broker                                    0207 614 5900

 Arden Partners plc
 Paul Shackleton                                                  info@arden-partners.com (mailto:info@arden-partners.com)
 Benjamin Onyeama-Christie

 Joint Broker
 Turner Pope Investments (TPI) Ltd                               0203 657 0050
 Andy Thacker                                                     info@turnerpope.com (mailto:info@turnerpope.com)

 James Pope

 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies
which are primarily used in critical care and general surgical procedures.
Deltex Medical's proprietary oesophageal Doppler monitoring (TrueVue Doppler)
measures blood flow velocity in the central circulation in real time. The
technology generates a low-frequency ultrasound signal which is highly
sensitive to changes in blood flow and measures such changes in 'real time'.
Deltex Medical is the only company in the enhanced haemodynamic monitoring
space to have built a robust and credible evidence base demonstrating both the
clinical and economic benefits of its core technology: TrueVue Doppler. This
technology has been proven in a wide range of clinical trials to reduce
complications suffered by patients after surgery and consequently can save
hospitals money.

Clinicians would like to be able to monitor the haemodynamic status of awake
patients not only in the operating room and intensive care departments.  Our
R&D programmes will provide the capability for Deltex Medical devices to
be used in A&E, including, for example, for the rapid detection of sepsis,
as well as on lower acuity wards or outside the hospital setting.

Deltex Medical is designing the next generation of non-invasive Doppler
ultrasound devices that will be released onto the TrueVue platform and will
accurately measure a non-sedated patient's haemodynamic status anywhere within
the hospital and not just for elective surgical patients.

Group goal

Haemodynamic management is now becoming widely accepted as a vital part of the
anaesthesia protocols for surgical patients, as well as treating ventilated
intensive care patients, including ventilated COVID-19 patients. There is also
a desire to start measuring haemodynamics on awake patients outside of the
operating room or intensive care departments, such as in lower acuity units or
in A&E. Our R&D programmes are targeting these broader applications.
Consequently, the Group's focus is on maximising value from the opportunities
associated with: the COVID-19 pandemic; the elective surgery backlog; the
risks associated with sepsis; awake patients and the higher profile of
haemodynamic monitoring which has arisen from recent consolidation in the
sector.

The Group aims to provide clinicians with a modern, next generation, single
'haemodynamic workstation' platform which offers them a range of technologies
from simple to sophisticated to be deployed according to the patient's
clinical condition as well as the skill and expertise of the user. Doing this
will enable the Group to partner with healthcare providers to support modern
haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a
number of territories worldwide, operating directly in the UK and the USA, and
via agreements with approximately 40 distributors overseas.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOESFSEFFEESELF